Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Starting soon
Conditions studied: ALS (Amyotrophic Lateral Sclerosis)
In brief
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.
Key facts
- Study ID
- NCT07737977
- Run by
- University Hospital, Montpellier
- People needed
- 200
- Starts
- 2026-08-01
- Expected to finish
- 2029-08-01
- Last updated by the study team
- 2026-07-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age greater than 18 years.
- Male and female patients with ALS diagnosed according to the El Escorial diagnostic criteria.
- Sporadic or familial ALS cases.
- Spinal-onset or bulbar-onset ALS cases.
You may not qualify if…
- Refusal to participate.
- Individuals deprived of liberty (Article L1121-6), including those subject to judicial or administrative decisions or involuntary hospitalization.
- Adults under legal protection (guardianship, curatorship, or judicial protection measures) (Article L1121-8).
- Individuals not affiliated with, or not beneficiaries of, a French social security scheme (Article L1121-8-1).
- Individuals participating in another research study with an ongoing exclusion period (Article L1121-12).
Where it is running
- Montpellier University Hospital — Montpellier, Occitanie, France
- Hospital Universitari Vall D'Hebron — Barcelona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.